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MaOBJECTIVES The value of the echocardiographic calcium score (eCS) was evaluated to predict cardiac events in a
multicenter cohort of subjects without known coronary disease, who underwent stress echocardiography (SE) for sus-
pected coronary artery disease (CAD).
BACKGROUND Several studies have established that aortic valve sclerosis and/or calciﬁcation andmitral calciﬁcation, as
detected by echocardiography, predict cardiovascular morbidity and mortality. The use of a semiquantitative total cardiac
calcium score (eCS) to assess aortic and mitral valves, papillary muscles, and the ascending aorta has never been tested in
multicenter studies; the inherent subjectivity and clinical applicability of such a parameter remains a concern.
METHODS We identiﬁed 1,303 patients from 5 Italian institutions and 1 U.S. institution, who had no known CAD and who
underwent clinically-indicated pharmacological or exercise SE. They were followed up for myocardial infarction (MI) and
all-cause death. eCS was assessed from archived images, and its discrimination and reclassiﬁcation prognostic potential
was determined.
RESULTS Fifty-eight patients met the combined endpoint of all-cause death (n ¼ 37; 2.8%) or MI (n ¼ 21; 1.6%) during
a median follow-up of 808 days. Age, diabetes mellitus, eCS >0, and ischemic SE were multivariate predictors of hard
events. Kaplan-Meier curves demonstrated that patients with ischemic SE or eCS >0 had worse outcomes. When both
variables were abnormal, the prognosis was worse (p < 0.001). The multivariate model demonstrated that both eCS and
ischemic SE independently contributed to risk prediction more than clinical variables. Both wall motion during SE and eCS
were able to signiﬁcantly reclassify the risk of events, but only stress wall motion demonstrated an incremental
discrimination value.
CONCLUSIONS eCS demonstrated signiﬁcant prognostic value in predicting hard cardiac events in a multicenter
population of patients who required noninvasive evaluation. Its value was independent from clinical assessment and
wall motion during SE, although it did not show incremental value over these factors for discrimination of patients
with and without events. (J Am Coll Cardiol Img 2015;8:389–96) © 2015 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
AVC = aortic valve
sclerosis/calciﬁcation
CAD = coronary artery disease
eCS = echocardiographic
calcium score
MAC = mitral annular
calciﬁcation
MI = myocardial infarction
NRI = net reclassiﬁcation
improvement
SE = stress echocardiograp
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390C alciﬁed plaques in the coronary ar-teries are markers of atheromatous-plaque burden, which, in turn, is
highly predictive of future cardiovascular
events and mortality (1). The coronary
calcium score (2), as assessed by cardiac
computed or electron-beam tomography,
has unequivocally demonstrated prognostic
superiority (added to clinical risk scores) to
screen asymptomatic subjects, compared
with biomarkers (e.g., C-reactive protein) or
established imaging parameters such as
carotid intima-media thickness (3,4). Conse-quently, European guidelines on cardiovascular dis-
ease prevention (5) support the use of the coronary
calcium score in asymptomatic adults at moderate
cardiovascular risk. A number of studies have estab-
lished that both aortic valve sclerosis/calciﬁcation
(AVC) and mitral annular calciﬁcation (MAC), as
detected by echocardiography, independently pre-
dict cardiovascular morbidity and mortality (6–9).
hySEE PAGE 397The use of echocardiographic semiquantitative cal-
cium scores (eCS), which comprehensively assess
aortic and mitral valves, papillary muscle, and the
ascending aorta—and range from no visible calcium
to severe and diffused calcium deposits—have also
been associated with: 1) coronary and total cardiac
calcium by computed tomography; 2) angiographic-
ally obstructive coronary artery disease (CAD); 3)
worse prognosis in several patient subgroups; and 4)
very recently, to ischemic stress echocardiography
(SE) results (10–18).
We aimed to evaluate the prognostic stratiﬁcation
value of a simple semiquantitative eCS to predict
future hard cardiac events in a large and multicenter
cohort of subjects without previously known coro-
nary disease, who underwent SE for clinical purposes.
METHODS
PATIENT POPULATION. We retrospectively identi-
ﬁed 1,303 patients from 5 European institutions and 1
U.S. institution who underwent clinically-indicated
SE during a previous 6-month period (the patients
were independently chosen in each center, based on
local availability of digitally archived SE images for
retrospective eCS assessment) for suspected CAD.
Exclusion criteria were: 1) known CAD and/or previ-
ous acute coronary syndrome or revascularization;
2) signiﬁcant valvular heart disease or previous
heart surgery: and 3) chronic renal insufﬁciency.
All patients provided written informed consent toresearch participation and collection of follow-up
data at the time of SE.
Patients’ age, sex, and presence of other CAD risk
factors (hypertension, diabetes mellitus, family his-
tory of premature CAD, and cigarette smoking) were
recorded in a prospectively collected database at the
time of SE, as is the current practice in each of the 6
study centers. Hypertension was deﬁned as systolic
blood pressure >140 mm Hg and diastolic blood
pressure >90 mm Hg, or current use of antihyper-
tensive medications. Diabetes mellitus was deﬁned as
a history of oral hypoglycemic drugs or insulin use, or
fasting blood glucose levels >126 mg/dl. Tobacco use
was deﬁned as currently smoking cigarettes. Family
history was deﬁned as CAD in ﬁrst-degree relatives,
in men <55 years of age, and in women <65 years of
age. Hypercholesterolemia was deﬁned as history of
total cholesterol >200 mg/dl or use of cholesterol-
lowering drugs. Obesity was deﬁned as a body mass
index $30 kg/m2.
STRESS ECHOCARDIOGRAPHY. SE was performed
using pharmacological stressors in 782 patients (60%)
(486 received dipyridamole 0.84 mg/kg/6 min and
296 received dobutamine up to 40 mg/kg þ atropine
up to 1 mg), whereas exercise echocardiography
(treadmill Bruce Protocol or semisupine cyclo-
ergometer) was used in 521 (40%) patients, depending
on patients’ contraindications and center prefer-
ences. SE, either pharmacological or with exercise,
was deﬁned as abnormal if new or worsening wall
motion abnormalities developed in at least 1 segment
during the stress phase, whereas it was deﬁned as
normal if wall motion did not change or improved.
Depending on the speciﬁc institution, Philips ie33
(Philips, Amsterdam, the Netherlands) or GE vivid
7 equipment (GE Healthcare, Little Chalfont, United
Kingdom) were used for the echocardiographic
examinations.
CALCIUM ASSESSMENT. All patients underwent
standard transthoracic echocardiography at rest as
part of their baseline examination before starting
their SE. Both baseline images acquired before
starting SE and the at rest clips of the SE protocol
(parasternal long-axis and short-axis views at mid-
ventricular and aortic levels, apical 4 chamber and
2-chamber views) were selected for the retrospective
assessment of semiquantitative eCS. Criteria for
judging AVC, MAC, ascending aorta, and papillary
muscle calcium were similar to grading systems used
in previous studies (10,11,14) and are detailed in
Table 1. Aortic valve sclerosis was deﬁned as focal
areas of increased echogenicity and thickening of the
aortic valve leaﬂets in the absence of aortic stenosis
TABLE 2 Baseline Characteristics of the Study Population
(N ¼ 1,303) and Echocardiographic Results
Mean age, yrs 63  12
Age $70 yrs 402 (31)
Male 740 (57)
Family history of CAD 328 (25)
Current cigarette smoking 253 (19)
Hypercholesterolemia 644 (49)
Diabetes mellitus 285 (22)
Hypertension 816 (63)
Obesity 216 (17)
Revascularization 125 (6)
Pharmacological stress test 766 (59)
Echocardiography at rest
Reduced LVEF at rest (<50%) 117 (9)
Total cardiac Ca score >0 542 (42)
MAC >0 318 (24)
AVC >0 330 (27)
SE result
Inducible wall motion abnormalities 162 (12)
Follow-up data and events
Revascularization within 3 mo of SE 96 (7.4)
All-cause death 37 (3)
Myocardial infarction 21 (2)
Values are mean  SD or n (%).
AVC ¼ aortic valve sclerosis/calciﬁcation; Ca ¼ calcium; CAD ¼ coronary artery
disease; eCS ¼ cardiac calcium score; LVEF ¼ left ventricular ejection fraction;
MAC ¼ mitral annular calciﬁcation; SE ¼ stress echocardiography.
TABLE 1 Grading System of Cardiac and Ascending Aortic Calcium
Grade
Papillary Muscle
Calcium
Mitral Annular
Calcium (mm)
Aortic Valve
Sclerosis
Ascending Aorta
Calcium
0 Absent Absent Absent Absent
1 Present Mild <5 Mild Present
2 Moderate 5–10 Moderate
3 Severe >10 Severe
Aortic valve sclerosis graded as follows: absent ¼ normal thickness <2 mm, and normal
reﬂectivity; mild ¼ thickness >2 mm and/or increased reﬂectivity; moderate ¼ thickness >4 mm
and/or diffuse or focal cusp hyper-reﬂectivity; severe ¼ thickness >6 mm and/or marked
echoreﬂectivity.
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391(velocity across the valve <2.5 m/s). Each aortic
valve leaﬂet was graded on a scale of 0 (normal) to
3 (severe) according to leaﬂet thickening and calciﬁc
deposits; the highest score for a given cusp was
assigned as the overall degree of aortic valve scle-
rosis. MAC was deﬁned as an intense and bright echo-
producing structure located at the junction of the
atrioventricular groove and posterior mitral valve
leaﬂet, and was measured from the leading anterior
to the trailing posterior edge and judged on a scale of
0 (normal) to 3 (severe). Papillary muscle calcium was
deﬁned as a bright echo involving the head of 1 or
both papillary muscles. Ascending aorta calcium was
deﬁned as a focal or diffuse area of increased echo-
reﬂectance and thickening in the aortic root on the
parasternal long-axis view. Accordingly, a ﬁnal score
was derived by the consensus of 2 readers in each
study site, as the sum of all identiﬁed cardiac calciﬁc
deposits; this score was in the range of 0 (no calcium
visible) to 8 (extensive cardiac and ascending aorta
calciﬁc deposits).
FOLLOW-UP. Outcome was determined from pa-
tients’ interviews at outpatient clinics, hospital chart
reviews, and telephone interviews with the patient,
relatives, or referring physician. Primary outcome
variables were death and nonfatal myocardial
infarction (MI). To avoid misclassiﬁcation of the
cause of death, we considered overall mortality (19).
MI was deﬁned by typical symptoms, and electro-
cardiographic and serial cardiac enzyme changes.
Follow-up time was considered starting from SE
date until the ﬁrst event or the last contact date.
Follow-up data were analyzed to evaluate event-free
survival according to classical risk factors, the left
ventricular ejection fraction at rest, eCS, and SE wall
motion response.
STATISTICAL ANALYSIS. Continuous variables were
expressed as mean  SD and categorical variables
were described as absolute number and percent.
Event-free survival time was estimated using
Kaplan-Meier curves, and the log-rank test was used
to compare curves. Univariate and multivariate Cox
proportional hazard models were used to estimate the
incidence of hard events. Variables with p < 0.1 at
univariate analysis or deemed to be clinically mean-
ingful, such as sex, were considered for the inclusion
in multivariate models. A model including only clin-
ical variables was ﬁrst developed, and then wall
motion and eCS were added. The clinical utility of the
addition of wall motion and eCS on clinical variables
was evaluated in terms of discrimination and
reclassiﬁcation ability. Harrell’s C index was used
to evaluate discrimination, and continuous netreclassiﬁcation improvement (NRI) was used for risk
reclassiﬁcation (20). Because of the inclusion of data
from different centers, the study center was used as a
strata variable, and pooled models over strata were
adapted. Analyses were also repeated by using center
as a covariate to check consistency of the results.
Multicollinearity was examined in all models, and
proportional hazard assumption was veriﬁed using
the Schoenfeld test. In all, the analysis of a dummy
variable was used for eCS, dichotomizing the contin-
uous variable according to the best cutoff identiﬁed
using receiver-operating characteristic curve analysis
and the highest Youden index. A p value <0.05
was considered statistically signiﬁcant. A total of
FIGURE 1 Calcium
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again 1 month later in the coordinating center by
consensus of the same 2 readers to assess eCS intra-
center agreement, according to a weighted Cohen’s k
test and intraclass correlation coefﬁcient. The same
30 examinations were also shared with the remaining
5 participating centers for intercenter agreement,
according to the intraclass correlation coefﬁcient.
Statistical analyses were performed using standard
software (Stata release 10 and R 2.11, StataCorp,
College Station, Texas).
RESULTS
BASELINE CLINICAL CHARACTERISTICS AND
ECHOCARDIOGRAPHY RESULTS. Baseline charac-
teristics of the study group (n ¼ 1,303) are shown in
Table 2; mean age was 63  12 years of age, and there
was slight male prevalence (57%). Total eCS was
higher than 0 in 542 patients (42%), and 98% of pa-
tients had scores 0 to 4. Figure 1 shows the distribu-
tion of eCS in the study population according to the
occurrence of events; it also shows the absolute
number of patients in each eCS category. ReversibleScore Distribution in the Study Population
ution in the study population on the basis of the occurrence of the
l-cause death or myocardial infarction), either based on the per-
ents with and without events in each calcium score category (top) or
ts with hard events in each calcium score category (bottom).wall motion abnormalities during SE were present in
162 patients (12%).
Patients with eCS >0 tested positive at SE more
frequently (17.3%; 94 of 542) than patients with
eCS ¼ 0 (8.9%, 68 of 761; p < 0.001), which indicated a
clear association between the presence of cardiac
calcium seen at echocardiography at rest (eCS >0) and
an ischemic result at SE.
REPRODUCIBILITY DATA. Reassessment of eCS at
30 random examinations, as previously described,
resulted in a weighted Cohen’s K ¼ 0.765 and intra-
class correlation coefﬁcient ¼ 0.91 for intracenter
variability, and an intraclass correlation coefﬁcient ¼
0.80 with regard to intercenter variability.
CLINICAL FOLLOW-UP RESULTS. Median follow-up
of the 1,303 enrolled patients was 808 days (lower
quartile 483 days, upper quartile 1,447 days). Fifty-
eight patients met the hard events combined
endpoint of all-cause death (n ¼ 37; 2.8%) or MI
(n ¼ 21; 1.6%) during the study follow-up.
The best cutoff for eCS to predict hard events from
the receiver-operating curve was eCS >0, using the
maximal Youden index method, with a sensitivity
and speciﬁcity of 74% and 60%, respectively, and an
area under the curve of 0.67 (SE 0.03).
PREDICTION OF HARD EVENTS BY CLINICAL AND
ECHOCARDIOGRAPHIC VARIABLES. Increasing age
and diabetes mellitus were the clinical variables that
were signiﬁcantly associated with the risk of hard
events at univariate analysis (Table 3), and their
independent contribution to the stratiﬁcation of
prognosis was demonstrated at multivariate analysis
(Table 4).
The 3-year event rate for patients with eCS >0 was
signiﬁcantly less favorable compared with subjects
with eCS ¼ 0 (9.8% vs 2.3%; p < 0.001).
Figure 2 demonstrates Kaplan-Meier survival cur-
ves for either normal (0) or abnormal (>0) eCS and
stress wall motion assessment. Data from both eCS
and wall motion assessment are shown in Figure 3,
which also shows the Kaplan-Meier survival curves
for the 4 subgroups corresponding to the possible
combinations of the 2 variables. Patients with both
wall motion abnormalities at SE and cardiac calciﬁ-
cations had the worst prognosis, with a 3-year event
rate of 24%, whereas patients with eCS ¼ 0 and no
wall motion abnormalities at SE had the best
outcome (2%) at the 3-year event rate (p < 0.001).
The multivariate model including eCS and wall
motion revealed that both variables independently
contributed to risk prediction. Findings were similar
when analyses were repeated using the study center
as a covariate.
TABLE 4 Multivariate Models for Prediction of Myocardial Infarction or Death Endpoint
HR (95% CI) p Value
Harrell’s C Index
(95% CI)
p Value Compared With
Previous Model
Clinical model
Female 0.70 (0.41–1.19) 0.192 0.739 (0.669–0.810) —
Age 1.07 (1.04–1.09) <0.001
Diabetes 1.83 (1.52–3.20) 0.032
Revascularization 3.33 (1.54–7.19) 0.002
Clinical model þ reversible wall motion
Female 0.68 (0.40–1.15) 0.151 0.784 (0.717–0.852) 0.028
Age 1.06 (1.03–1.09) <0.001
Diabetes 1.95 (1.12–3.40) 0.019
Revascularization 2.45 (1.11–5.39) 0.026
Inducible WM
abnormalities
2.95 (1.58–5.53) 0.001
Clinical model þ reversible wall motion þ eCS
Female 0.65 (0.38–1.10) 0.105 0.792 (0.727–0.856) 0.609
Age 1.05 (1.02–1.08) <0.001
Diabetes 1.80 (1.03–3.15) 0.040
Revascularization 2.54 (1.15–5.64) 0.021
Inducible WM
abnormalities
2.71 (1.44–5.11) 0.002
eCS >0 2.61 (1.40–4.86) 0.002
WM ¼ wall motion; other abbreviations as in Tables 2 and 3.
TABLE 3 Univariate Stratiﬁed Models and Cox Analysis for Myocardial Infarction
or Death Endpoint
HR (95% CI) SE Z p Value
Sex 0.820 (0.486–1.385) 0.219 0.740 0.458
Age 1.067 (1.040–1.095) 0.014 4.950 0.000
Family history of CAD 1.268 (0.719–2.239) 0.368 0.820 0.412
Smoking history 1.224 (0.686–2.186) 0.362 0.680 0.494
Hypercholesterolemia 0.862 (0.510–1.457) 0.231 0.560 0.579
Diabetes 2.045 (1.181–3.539) 0.572 2.550 0.011
Hypertension 1.078 (0.613–1.893) 0.310 0.260 0.795
Obesity 1.286 (0.657–2.516) 0.440 0.730 0.463
Revascularization after 3 mo 5.128 (2.404–10.938) 1.982 4.230 0.000
LVEF <50% 1.652 (0.852–3.204) 0.558 1.490 0.137
Inducible wall motion abnormalities 4.265 (2.346–7.754) 1.301 4.760 0.000
eCS >0 3.685 (2.024–6.709) 1.127 4.270 0.000
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 2.
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393INCREMENTAL PROGNOSTIC VALUE OF WALL MOTION
AND eCS TO PREDICT HARD EVENTS. Discrimination.
Compared with the baseline multivariate clinical
model, the addition of stress wall motion data
showed signiﬁcantly better discrimination ability
(Harrell’s C index: 0.784; 95% conﬁdence interval
[CI]: 0.717 to 0.852 vs. Harrell’s C index: 0.739; 95%
CI: 0.669 to 0.810; p ¼ 0.028), whereas the further
addition of eCS to the clinical þ stress wall motion
model did not improve the discrimination ability of
the model (Harrell’s C index: 0.79; 95% CI: 0.727 to
0.856 vs. Harrell’s C index: 0.784; 95% CI: 0.717 to
0.852; p ¼ 0.609) (Table 4).
Reclassiﬁcation. Results from continuous NRI analysis
demonstrated the signiﬁcant and relevant incre-
mental reclassiﬁcation value of the addition of either
stress wall motion data (continuous NRI: 0.28; 95%
CI: 0.04 to 0.52; p ¼ 0.021) or eCS (NRI: 0.58; 95% CI:
0.34 to 0.83; p < 0.001) compared with clinical data
and also of eCS over clinical and stress wall motion
data (NRI: 0.57; 95% CI: 0.32 to 0.82; p < 0.001).
DISCUSSION
The main ﬁnding of our multicenter study was that
for the ﬁrst time we found a signiﬁcant independent
prognostic value of a semiquantitative eCS to predict
hard cardiac events in a population of subjects with
symptoms that required noninvasive evaluation for
suspected CAD.
The prognostic yield of eCS was independent from
clinical variables and stress wall motion data, but it
was not able to discriminate them incrementally by
comparison to the Harrell’s C index of the models
without and with eCS. In contrast, the addition of eCS
was able to reclassify the risk of events, again
compared with the model that included clinical and
stress wall motion data, but this NRI method has
recently been heavily criticized for its risk of frequent
false positive results (21,22).
In contrast, the low sensitivity of C statistics for
improvement in discrimination, in particular when
the baseline comparison model has high C values (as
the clinical þ stress wall motion model in our study),
is well known (23,24).
In conclusion, in the absence of an associated sig-
niﬁcant difference in the Harrell’s C index of the
models for discrimination, with an isolated contin-
uous NRI suggesting the signiﬁcant incremental
prognostic value of eCS, we should conservatively
and cautiously conclude that eCS in our study failed
to demonstrate an incremental value on top of clinical
and stress wall motion data. This was the ﬁrst study
that reported intracenter and intercenter variabilitydata for eCS assessment. The variability was key to
evaluate its clinical usefulness when testing partially
subjective and semiquantitative variables, such as
eCS. Repeatability of eCS among the involved centers
was good (intraclass correlation coefﬁcient ¼ 0.8) and
sufﬁciently robust to be reliably applied in clinical
practice.
Noninvasive modalities for the diagnosis of CAD
are key for risk stratiﬁcation of symptomatic pa-
tients, and to identify higher risk subjects who could
beneﬁt more from invasive coronary angiography
and possible subsequent revascularization (or in
alternative maximal medical therapy). Transthoracic
FIGURE 2 Kaplan-Meier Event-Free Survival Curves
Kaplan-Meier event-free survival curves, divided on the basis of echocardiographic calcium score (eCS) >0 at rest, echocardiography (left) or reversible wall motion
(WM) abnormalities at stress-echocardiography (right). Log-rank p values are superimposed.
FIGURE 3 Kaplan-
Kaplan-Meier event-
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394echocardiography has the advantage of being a sim-
ple, low-cost, radiation-free technique, which is
widely available in clinical practice. Although our
study patients represented a mixed cohort of patients
who underwent SE for clinical purposes, theyMeier Event-Free Survival Curves
free survival curves according to the presence and/or absence of
aphic calcium score (eCS) >0 at rest, echocardiography, and/or
n (WM) abnormalities. Log-rank p values are superimposed.were generally symptomatic and considered at
intermediate-risk, and their all-cause mortality rate
(2.9% at 3 years) was lower than expected. Therefore,
we speculate the value of eCS for risk stratiﬁcation
might eventually be extended to lower risk subjects,
although this hypothesis needs prospective testing in
an asymptomatic population. Interestingly, the best
eCS cutoff to predict cardiac events was >0, which is
probably the easiest score to apply clinically, because
accordingly, eCS is “abnormal” whatever amount of
calcium is present, in at least 1 of the pre-determined
cardiac sites.
Although the present study proved the signiﬁcant
prognostic value of a eCS >0 in a population of
patients who underwent SE, it did not clarify how this
parameter should be used clinically. Patients with
both abnormal eCS and stress wall motion abnor-
malities had the worst prognoses in our study and
might be the patients who beneﬁt more from inten-
sive medical and/or interventional therapies.
STUDY LIMITATIONS. Different institutions with
very different case mix and investigator’s preferences
towards exercise or pharmacologic SE were involved
in our multicenter study, so that the study population
was very heterogeneous among centers. Further-
more, it was a lower risk population than expected for
patients who underwent SE; this is in line with
current overuse of provocative testing in western
societies. Thus, we could not assess the incremental
prognostic value of increasing eCS values due to the
FIGURE 4 Example of Calciﬁcations Imaged in Parallel by Echocardiography and Cardiac Computed Tomography
An example of calciﬁcations imaged by echocardiography (right) and cardiac computed tomography (left/middle) obtained from patients who
underwent cardiac computed tomography following stress-echocardiography. Arrows indicate calciﬁcations.
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395low percent of cases with scores >4. This was also a
retrospective study, and clinical data collection was
consequently limited to a minimal common data set
prospectively collected by all involved centers. The
echocardiographic detection of calcium relies on the
ability of ultrasound to identify even a minimal
quantity of calcium. In contrast, increased echolu-
cency caused by ﬁbrosis might be misinterpreted as
calciﬁcation, and in addition, there might have been
difﬁculty in ensuring independence of the eCS and SE
reads, although this was probably only a minor
problem because eCS was assessed (retrospectively)
on archived images taken at rest.
Figure 4 shows examples of calciﬁcations imaged
in parallel by echocardiography and cardiac com-
puted tomography, obtained from patients who
clinically underwent cardiac computed tomography
following SE.CONCLUSIONS
The assessment of an eCS at the time of SE has
a signiﬁcant and independent prognostic value,
although it appears that it does not add incrementally
to the combination of clinical and stress wall motion
data. Because such an assessment appears reproduc-
ible and adds virtually no additional cost to the pa-
tient, it should be considered as a recommended
additional diagnostic assessment at the time of SE.
Further prospective evaluation is needed to deter-
mine the role of eCS in altering patient management
or in speciﬁc subsets of patients.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The use
of a simple semiquantitative eCS, which is obtained by
visually assessing the aortic and mitral valves, papillary
muscles, and the ascending aorta, has been now tested in
a multicenter study involving patients who underwent SE.
eCS proved robust, reproducible, and was able to stratify
future cardiovascular prognoses independently from wall
motion behavior during SE.
TRANSLATIONAL OUTLOOK: The inherent subjec-
tivity of such a visually assessed parameter as eCS
remains a limitation, and future studies should address
objective quantitative measures of cardiac calcium.
Additional clinical studies, such as those typical of
primary prevention studies, are still needed to conﬁrm
the prognostic value of eCS in lower risk patients.
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